Skip to main content
Top
Published in: International Journal of Hematology 3/2020

01-09-2020 | Lymphoma | Rapid Communication

A high-throughput detection method for the clonality of Human T-cell leukemia virus type-1-infected cells in vivo

Authors: Masumichi Saito, Hiroo Hasegawa, Shunsuke Yamauchi, So Nakagawa, Daisuke Sasaki, Naganori Nao, Michikazu Tanio, Yusaku Wada, Takahiro Matsudaira, Haruka Momose, Madoka Kuramitsu, Makoto Yamagishi, Makoto Nakashima, Shingo Nakahata, Hidekatsu Iha, Masao Ogata, Yoshitaka Imaizumi, Kaoru Uchimaru, Kazuhiro Morishita, Toshiki Watanabe, Yasushi Miyazaki, Katsunori Yanagihara

Published in: International Journal of Hematology | Issue 3/2020

Login to get access

Abstract

Approximately 10–20 million of Human T-cell leukemia virus type-1 (HTLV-1)-infected carriers have been previously reported, and approximately 5% of these carriers develop adult T-cell leukemia/lymphoma (ATL) with a characteristic poor prognosis. In Japan, Southern blotting has long been routinely performed for detection of clonally expanded ATL cells in vivo, and as a confirmatory diagnostic test for ATL. However, alternative methods to Southern blotting, such as sensitive, quantitative, and rapid analytical methods, are currently required in clinical practice. In this study, we developed a high-throughput method called rapid amplification of integration site (RAIS) that could amplify HTLV-1-integrated fragments within 4 h and detect the integration sites in > 0.16% of infected cells. Furthermore, we established a novel quantification method for HTLV-1 clonality using Sanger sequencing with RAIS products, and the validity of the quantification method was confirmed by comparing it with next-generation sequencing in terms of the clonality. Thus, we believe that RAIS has a high potential for use as an alternative routine molecular confirmatory test for the clonality analysis of HTLV-1-infected cells.
Appendix
Available only for authorised users
Literature
1.
go back to reference Doi K, Wu X, Taniguchi Y, Yasunaga J, Satou Y, Okayama A, et al. Preferential selection of human T-cell leukemia virus type I provirus integration sites in leukemic versus carrier states. Blood. 2005;106:1048–53.CrossRef Doi K, Wu X, Taniguchi Y, Yasunaga J, Satou Y, Okayama A, et al. Preferential selection of human T-cell leukemia virus type I provirus integration sites in leukemic versus carrier states. Blood. 2005;106:1048–53.CrossRef
2.
go back to reference Artesi M, Marcais A, Durkin K, Rosewick N, Hahaut V, Suarez F, et al. Monitoring molecular response in adult T-cell leukemia by high-throughput sequencing analysis of HTLV-1 clonality. Leukemia. 2017;31:2532–5.CrossRef Artesi M, Marcais A, Durkin K, Rosewick N, Hahaut V, Suarez F, et al. Monitoring molecular response in adult T-cell leukemia by high-throughput sequencing analysis of HTLV-1 clonality. Leukemia. 2017;31:2532–5.CrossRef
3.
go back to reference Firouzi S, Lopez Y, Suzuki Y, Nakai K, Sugano S, Yamochi T, et al. Development and validation of a new high-throughput method to investigate the clonality of HTLV-1-infected cells based on provirus integration sites. Genome Med. 2014;6:46.CrossRef Firouzi S, Lopez Y, Suzuki Y, Nakai K, Sugano S, Yamochi T, et al. Development and validation of a new high-throughput method to investigate the clonality of HTLV-1-infected cells based on provirus integration sites. Genome Med. 2014;6:46.CrossRef
4.
go back to reference Gillet NA, Malani N, Melamed A, Gormley N, Carter R, Bentley D, et al. The host genomic environment of the provirus determines the abundance of HTLV-1-infected T-cell clones. Blood. 2011;117:3113–222.CrossRef Gillet NA, Malani N, Melamed A, Gormley N, Carter R, Bentley D, et al. The host genomic environment of the provirus determines the abundance of HTLV-1-infected T-cell clones. Blood. 2011;117:3113–222.CrossRef
5.
go back to reference Miyazato P, Katsuya H, Fukuda A, Uchiyama Y, Matsuo M, Tokunaga M, et al. Application of targeted enrichment to next-generation sequencing of retroviruses integrated into the host human genome. Sci Rep. 2016;6:28324.CrossRef Miyazato P, Katsuya H, Fukuda A, Uchiyama Y, Matsuo M, Tokunaga M, et al. Application of targeted enrichment to next-generation sequencing of retroviruses integrated into the host human genome. Sci Rep. 2016;6:28324.CrossRef
6.
go back to reference Gabriel R, Eckenberg R, Paruzynski A, Bartholomae CC, Nowrouzi A, Arens A, et al. Comprehensive genomic access to vector integration in clinical gene therapy. Nat Med. 2009;15:1431–6.CrossRef Gabriel R, Eckenberg R, Paruzynski A, Bartholomae CC, Nowrouzi A, Arens A, et al. Comprehensive genomic access to vector integration in clinical gene therapy. Nat Med. 2009;15:1431–6.CrossRef
7.
go back to reference Paruzynski A, Arens A, Gabriel R, Bartholomae CC, Scholz S, Wang W, et al. Genome-wide high-throughput integrome analyses by nrLAM-PCR and next-generation sequencing. Nat Protoc. 2010;5:1379–95.CrossRef Paruzynski A, Arens A, Gabriel R, Bartholomae CC, Scholz S, Wang W, et al. Genome-wide high-throughput integrome analyses by nrLAM-PCR and next-generation sequencing. Nat Protoc. 2010;5:1379–95.CrossRef
8.
go back to reference Tamiya S, Matsuoka M, Etoh K, Watanabe T, Kamihira S, Yamaguchi K, et al. Two types of defective human T-lymphotropic virus type I provirus in adult T-cell leukemia. Blood. 1996;88:3065–73.CrossRef Tamiya S, Matsuoka M, Etoh K, Watanabe T, Kamihira S, Yamaguchi K, et al. Two types of defective human T-lymphotropic virus type I provirus in adult T-cell leukemia. Blood. 1996;88:3065–73.CrossRef
9.
go back to reference Kuramitsu M, Okuma K, Yamagishi M, Yamochi T, Firouzi S, Momose H, et al. Identification of TL-Om1, an adult T-cell leukemia (ATL) cell line, as reference material for quantitative PCR for human T-lymphotropic virus 1. J Clin Microbiol. 2015;53:587–96.CrossRef Kuramitsu M, Okuma K, Yamagishi M, Yamochi T, Firouzi S, Momose H, et al. Identification of TL-Om1, an adult T-cell leukemia (ATL) cell line, as reference material for quantitative PCR for human T-lymphotropic virus 1. J Clin Microbiol. 2015;53:587–96.CrossRef
10.
go back to reference Maeda M, Shimizu A, Ikuta K, Okamoto H, Kashihara M, Uchiyama T, et al. Origin of human T-lymphotrophic virus I-positive T cell lines in adult T cell leukemia. Analysis of T cell receptor gene rearrangement. J Exp Med. 1985;162:2169–74.CrossRef Maeda M, Shimizu A, Ikuta K, Okamoto H, Kashihara M, Uchiyama T, et al. Origin of human T-lymphotrophic virus I-positive T cell lines in adult T cell leukemia. Analysis of T cell receptor gene rearrangement. J Exp Med. 1985;162:2169–74.CrossRef
11.
go back to reference Watanabe T. Adult T-cell leukemia: molecular basis for clonal expansion and transformation of HTLV-1-infected T cells. Blood. 2017;129:1071–81.CrossRef Watanabe T. Adult T-cell leukemia: molecular basis for clonal expansion and transformation of HTLV-1-infected T cells. Blood. 2017;129:1071–81.CrossRef
12.
go back to reference Firouzi S, Farmanbar A, Nakai K, Iwanaga M, Uchimaru K, Utsunomiya A, et al. Clonality of HTLV-1-infected T cells as a risk indicator for development and progression of adult T-cell leukemia. Blood Adv. 2017;1:1195–205.CrossRef Firouzi S, Farmanbar A, Nakai K, Iwanaga M, Uchimaru K, Utsunomiya A, et al. Clonality of HTLV-1-infected T cells as a risk indicator for development and progression of adult T-cell leukemia. Blood Adv. 2017;1:1195–205.CrossRef
13.
go back to reference Kataoka K, Nagata Y, Kitanaka A, Shiraishi Y, Shimamura T, Yasunaga J, et al. Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet. 2015;47:1304–15.CrossRef Kataoka K, Nagata Y, Kitanaka A, Shiraishi Y, Shimamura T, Yasunaga J, et al. Integrated molecular analysis of adult T cell leukemia/lymphoma. Nat Genet. 2015;47:1304–15.CrossRef
14.
go back to reference Katsuya H, Islam S, Tan BJY, Ito J, Miyazato P, Matsuo M, et al. The nature of the HTLV-1 provirus in naturally infected individuals analyzed by the viral DNA-capture-seq approach. Cell Rep. 2019;29:724–735 e4.CrossRef Katsuya H, Islam S, Tan BJY, Ito J, Miyazato P, Matsuo M, et al. The nature of the HTLV-1 provirus in naturally infected individuals analyzed by the viral DNA-capture-seq approach. Cell Rep. 2019;29:724–735 e4.CrossRef
15.
go back to reference Kluesner MG, Nedveck DA, Lahr WS, Garbe JR, Abrahante JE, Webber BR, et al. EditR: a method to quantify base editing from Sanger sequencing. CRISPR J. 2018;1:239–50.CrossRef Kluesner MG, Nedveck DA, Lahr WS, Garbe JR, Abrahante JE, Webber BR, et al. EditR: a method to quantify base editing from Sanger sequencing. CRISPR J. 2018;1:239–50.CrossRef
16.
go back to reference Iwanaga M, Watanabe T, Utsunomiya A, Okayama A, Uchimaru K, Koh KR, et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood. 2010;116:1211–9.CrossRef Iwanaga M, Watanabe T, Utsunomiya A, Okayama A, Uchimaru K, Koh KR, et al. Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan. Blood. 2010;116:1211–9.CrossRef
Metadata
Title
A high-throughput detection method for the clonality of Human T-cell leukemia virus type-1-infected cells in vivo
Authors
Masumichi Saito
Hiroo Hasegawa
Shunsuke Yamauchi
So Nakagawa
Daisuke Sasaki
Naganori Nao
Michikazu Tanio
Yusaku Wada
Takahiro Matsudaira
Haruka Momose
Madoka Kuramitsu
Makoto Yamagishi
Makoto Nakashima
Shingo Nakahata
Hidekatsu Iha
Masao Ogata
Yoshitaka Imaizumi
Kaoru Uchimaru
Kazuhiro Morishita
Toshiki Watanabe
Yasushi Miyazaki
Katsunori Yanagihara
Publication date
01-09-2020
Publisher
Springer Singapore
Keywords
Lymphoma
Leukemia
Published in
International Journal of Hematology / Issue 3/2020
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-020-02935-5

Other articles of this Issue 3/2020

International Journal of Hematology 3/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine